Servicenow's Impact in Genome Technology and Gene Therapy Companies

Sravanthi Mallireddy

Software Developer

Abstract

This thesis investigates ServiceNow's disruptive influence in the field of genome technology and gene therapy enterprises. As these industries rely more on data-driven insights and operational efficiency, ServiceNow's digital workflow solutions provide considerable benefits. ServiceNow helps to drive innovation in gene therapy and genomic research by automating procedures, improving collaboration, and guaranteeing regulatory compliance. This study will look at how ServiceNow affects operational workflows, data management, and patient involvement in these specialized sectors. This study uses case studies and industry analysis to show the benefits, limitations, and future potential of integrating ServiceNow into genome technology and gene therapy businesses.

Keywords: Genome technology, ServiceNow and Data- Driven Strategies

Genome technology and Gene therapy:

On the other hand, omatic gene editing therapies promise to treat a variety of illnesses and ailments, such as tumors, blindness, and hemophilia, without the same risks and difficulties. About 136 clinical trials have been registered in the WHO Human Genome Editing Registry thus far.

Human genome editing medicines currently cost between $253,000 and $1.8 million. The biopharmaceutical industry spends a significant amount of money on research and development (R&D), which is time-consuming, costly, and fraught with danger in the event that a product fails to materialize into a viable medication or treatment. This is one reason for the high cost.

Over the course of the projected period, increasing funding for genetic research in developed regions, such as North America, will propel the expansion of the gene editing market. To create practical materials, tools, and techniques, government research and development companies in the United States were financed by over 20 federal agencies. Additionally, the United States government provides funding to a number of research organizations that support the creation and production of medications for a range of uncommon genetic illnesses. For example, the National Human Genome Research Institute funds projects and research initiatives to progress the area of genomics.

Similarly, the nation's medical research agency, the National Institutes of Health (NIH), which is a division of the U.S. government's Health and Human Services, is in charge of genetic and biological research. In 2021, the NIH provided funding of about USD 1.6.

The majority of monogenic human disorders are uncommon, meaning that only a limited number of people are treatable (some gene therapies target as few as 1,000– 2,000 patients5), which contributes to the high expense of genetic medicines. The final cost of the therapy is high when future profits for novel medications or treatments are anticipated to come from such a small number of patients, as the corporation anticipates a healthy return on investment. Up until recently, genetic therapy businesses have given preference to patients residing in wealthy nations due to their access to payment systems or

personal financial means. Targeting orphan or rare diseases is financially motivated by the biotech business model's present high return on investment.

The fields of genome technology and gene therapy are at the forefront of medical innovation, promising advancements in personalized medicine and targeted treatments. However, these sectors face unique challenges, including complex regulatory requirements, the need for precise data management, and the necessity for rapid innovation. As organizations strive to keep pace with technological advancements and market demands, digital solutions like ServiceNow emerge as essential tools for enhancing operational efficiency. [1][2]

Background Overview of Genome Technology and Gene Therapy Genome technology refers to a variety of approaches used to examine and modify genetic material. This includes sequencing technologies, CRISPR gene editing, and bioinformatics tools that help in genomic research. Gene therapy entails employing these technologies to treat or prevent diseases by altering genes within an individual's cells. Current trends: The global gene therapy industry is expected to reach $13 billion by 2026, owing to increased spending in R&D. Key players: Major businesses including as Novartis, Gilead Sciences, and Spark Therapeutics are driving innovation in this area.

The growth of various gene-editing technologies between2021 and forecasts for 2030 is shown in the figure "Global Gene Market by Technology, 2022 & 2030 (USD Million)". Transcription Activator-Like Effector Nucleases (TALENs), Zinc Finger Nucleases (ZFNs), CRISPR/Cas9, and other technologies are contrasted in the chart as shown in below figure Figure 1: Global Gene Market by Technology,2022 &2030 (USD Million

In CRISPR/Cas9 market value of CRISPR/Cas9 was around $15 million USD in 2021.It is expected to expand the fastest of all the technologies by 2030, reaching a value of roughly30 million USD.

In ZFNs 2021, the ZFN market was valued at roughly 10 million USD.It is anticipated to rise to around 20 million USD by 2030, indicating a moderate development trend. TALENs:In 2021, the TALEN market size is smaller, about $5 million. However, it is expected to increase to $15 million by 2030. By 2030, this segment will grow to nearly $10 million.

The data shows that CRISPR/Cas9 will be the dominant technology, in 2021 and 2030, and the market will grow.Although ZFN and TALEN have a smaller market share, they are expected to continue to grow over time.Other technologies, although with a much smaller market share, show progress that reflects the diversity and evolution of gene editing solutions. In summary, the market for gene editing is growing, with CRISPR/Cas9 leading the way due to its widespread use and success in biotechnology. Other technologies are still evolving, albeit at a slower pace. This represents innovation and development in genetic engineering..



Figure 1: Global Gene Market by Technology,2022 &2030 (USD Million)

The Role of Digital Transformation:

Digital transformation is transforming the healthcare industry by integrating cutting-edge technologies that improve patient care and expedite operational operations. Telemedicine, electronic health records (EHR), and data analytics are fundamentally changing how healthcare providers engage with patients and handle information. Telemedicine, for example, has increased access to care by allowing patients to consult with healthcare professionals remotely, which is especially useful for individuals living in disadvantaged areas. Meanwhile, EHR systems allow for the easy sharing of patient data among doctors, enhancing coordination and decision- making. The application of artificial intelligence (AI) is also increasing, assisting in diagnoses and individualized treatment plans based on individual patient data. Many firms continue to face substantial obstacles, such as integrating legacy systems and ensuring data security.

Benefits of Service Now in Genome Technology and Gene Therapy:

Enhanced Workflow Automation: ServiceNow automates repetitive operations including data entry, compliance checks, and reporting. This automation lowers human mistake and allows academics to focus on more important parts of their work. Case Study Example: A top gene therapy company used ServiceNow to automate its clinical trial management process, which resulted in a 30% reduction in administrative effort.

Figure 2: Genome Technology

Improved Data Management

ServiceNow's integrated platform provides efficient data administration across multiple departments. Researchers can gain real-time data insights that aid in decision-making processes. Integration Capabilities: ServiceNow interfaces with laboratory information management systems (LIMS) and electronic lab notebooks (ELNs) to ensure smooth data flow. Data Security: Improved security characteristics Protect sensitive genetic information while complying with rules such as HIPAA.[3][4]
Regular Compilance The biotechnology sector is highly regulated. ServiceNow assists firms in adhering to FDA rules by providing solutions for document keeping, audit management, and Good Laboratory Practices (GLP) compliance. Audit Trails: ServiceNow's automated audit trails make compliance reporting easier during inspections.
Compliance Dashboards: Custom dashboards provide real- time information about compliance status across departments.

Enhanced Collaboration

ServiceNow promotes collaboration among interdisciplinary teams by offering a unified platform for communication and project management. This skill is critical for initiatives that require input from geneticists, doctors, regulatory specialists, and information technology professionals. Project Management Tools: Features like as task assignments, progress monitoring, and shared documentation improve team coordination. Cross-Functional Collaboration: With integrated communication technologies, team members can have real-time talks regardless of their location.[8]

Figure 3: Imageine challenges in Service now

Challenges in Implementing ServiceNow

Integration of Existing Systems Many genomic technology firms use old systems that may not be easily integrated with current platforms like as ServiceNow. [7]This problem may impede the seamless adoption of new technology. Solution strategies: Prior to integrating ServiceNow, organizations must conduct extensive assessments of their existing IT infrastructure to detect potential integration concerns. Middleware Solutions: Middleware can help to improve integration between legacy systems and ServiceNow as shown in above Figure 3: Imageine challenges in Service now.

Case Studies

Case Study #1: A Leading Gene Therapy Company A well- known gene therapy company used ServiceNow to improve its clinical trial processes. Automate participant tracking and data collecting processes. The company results claimed a 40% reduction in time spent on administrative chores linked to clinical trials. Impact on Innovation: Researchers were free to concentrate on scientific research rather than paperwork.[5][6]



Figure 4: Case study 1 Leading Gene Therapy Company Case Study #2: Genomic Research Institute A genetic research institute uses ServiceNow to handle bioinformatics workflows. The platform improved collaboration amongst academics working on large-scale genomic projects: Results: Enhanced data sharing resulted in a 25% increase in project completion rates. Patient Engagement: The institute used ServiceNow's customer service management tools to better communication with study participants.

Future Prospects

Expanding Use Cases As genomic technology advances, the scope of ServiceNow's applications will grow. Future improvements could include incorporating AI-driven analytics for predictive modeling in genetic studies. AI Integration: Using AI could improve patient stratification in clinical trials by identifying suitable individuals based on genetic characteristics.

Continuous Improvement using Feedback Loops Implementing feedback tools within ServiceNow can help firms continuously improve their procedures based on user feedback. This iterative approach guarantees that services are constantly relevant and responsive to changing needs.

Conclusion:

The integration of ServiceNow into genome technology and gene therapy enterprises is a key step toward improving operational efficiency and encouraging innovation. By automating procedures, improving data management, maintaining regulatory compliance, and increasing team collaboration, ServiceNow enables enterprises to effectively negotiate the intricacies of modern genetic research. While hurdles abound, particularly in terms of interface with legacy systems, successful implementations show the potential for improved service delivery in these specialized domains. As the landscape evolves, adopting digital transformation platforms such as ServiceNow will be critical for developing genomic medicine and improving patient outcomes.

REFERENCES:

1. S. Ahmar, T. Mahmood, S. Fiaz, F. MoraPoblete, M.S. Shafique, M.S. Chattha, K.-H. JungAdvantage of nanotechnol0gy based genome editing system and its application incrop improvement Front. Plant Sci. (2021), p. 12, 10.3389/fpls.2021.663849
2. X. Huang, D. Yang, J. Zhang, J. Xu, Y.E. Chen Recent advances in improving gene-editing specificity through CRISPR-cas9 nuclease engineering Cells, 11 (2022),
3. H. Tang, X. Zhao, X. Jiang Synthetic multi-layer nanoparticles for CRISPR-Cas9 genome editing Adv. Drug Deliv,Rev., 168(2021) , pp. 55-78,
4. D. Allen, M. Rosenberg, A. HendelUsing synthetically engineered guide RNAs to enhance CRISPR genome editing systems in mammalian cells Frontiers in Genome Editing, 2 (2021), Article 617910
5. Books Gene Therapy: Principles and Practice by John W. Engelhardt
6. Genomics: A Very Short Introduction by Paul Billings Bioinformatics for Beginners: Genes, Genomes, Molecular
7. Alhakamy, N. A., Curiel, D. T. & Berkland, C. J. *Drug Disc. Today* **26**, 1602–1619 (2021).
8. "A Literature review of Current Technologies on Health Data Integration for Patient-Centered Health

Management", Health Informatics Journal. [6] Bahae Samhan (2017)
9. "Patients' Resistance toward Health Information Technology: A perspective of the Dual Factor Model of IT Usage", 50th Hawaii Conference on System Sciences (2017).
10. Gene Editing Market Size and Share | Industry Statistics - 2030
11. K. Hiranniramol, Y. Chen, W. Liu, X. WangGeneralizablesg RNA design for improved CRISPR/Cas9 editing efficiency Bioinformatics, 36 (2020), pp. 2684-2689,